{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:02:42Z","timestamp":1747184562266,"version":"3.40.5"},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>The prognosis of diffuse large B\u2010cell lymphoma (DLBCL) patients with refractory or multiply relapsed (R\/R) disease is disappointing. Pixantrone is currently approved as third or fourth line regimen, with encouraging results, even if long\u2010term follow\u2010up data are limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this post\u2010hoc analysis of our observational study, we retrospectively investigated disease outcome and clinical characteristics of 16 R\/R DLBCL patients who achieved a complete response with pixantrone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Pixantrone was administered as third or fourth line in 12\/16 (75%) and 4\/16 (25%) cases. After a median follow\u2010up of 24\u2009months, 14\/16 patients (87.5%) were alive (causes of death were progressive disease and secondary acute myeloid leukemia, one case each). Median progression\u2010free survival was 23.8\u2009months, median duration of response was 17.8\u2009months and median overall survival (OS) was not reached (2\u2010years OS was 84%). A significant proportion of patients achieved a long\u2010lasting response &gt;12\u2009months (7\/16 cases). Response to prior therapy did not influence long\u2010term remission after pixantrone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this real\u2010life experience, pixantrone demonstrated long\u2010term efficacy in a cohort of R\/R DLBCL cases who had previously received at least two prior regimens; many of whom had characteristics associated with poor prognosis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13989","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T03:39:35Z","timestamp":1683776375000},"page":"247-253","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long\u2010term efficacy in patients with relapsed\/refractory diffuse large B\u2010cell lymphoma achieving a complete response with pixantrone"],"prefix":"10.1111","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0432-9706","authenticated-orcid":false,"given":"Emanuele","family":"Cencini","sequence":"first","affiliation":[{"name":"Unit of Hematology Azienda Ospedaliera Universitaria Senese and University of Siena  Siena Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melania","family":"Rocco","sequence":"additional","affiliation":[{"name":"SOC Oncoematologia, SOS Firenze  Florence Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Ghio","sequence":"additional","affiliation":[{"name":"Unit of Hematology Azienda Ospedaliera Universitaria Pisana and University of Pisa  Pisa Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Simonetti","sequence":"additional","affiliation":[{"name":"UOC Ematologia Aziendale, Ospedale Versilia, Lido di Camaiore  Camaiore Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annarosa","family":"Cuccaro","sequence":"additional","affiliation":[{"name":"UOC Ematologia Aziendale, Azienda USL Toscana Nordovest, Spedali Riuniti  Livorno Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"De Marco","sequence":"additional","affiliation":[{"name":"Unit of Hematology Ospedale S. Giovanni Bosco ASL  Citt\u00e0 di Torino Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Consoli","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Department of Biotechnology and Health Sciences University of Torino  Torino Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[{"name":"Unit of Hematology Azienda Ospedaliera Universitaria Senese and University of Siena  Siena Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Fabbri","sequence":"additional","affiliation":[{"name":"Unit of Hematology Azienda Ospedaliera Universitaria Senese and University of Siena  Siena Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv304"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70235-2"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281407"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00403-1"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15412"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100640"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005794"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004155"},{"key":"e_1_2_10_12_1","article-title":"The European medicines agency review of Tafasitamab in combination with Lenalidomide for the treatment of adult patients with relapsed\/refractory diffuse large B\u2010cell lymphoma","volume":"5","author":"Delgado J","year":"2021","journal-title":"Hema"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.275958"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002587"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1986219"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.101002"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1010505"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70212-7"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14101"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14021"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0635-3"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13745"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13831"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00139-X"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01969-y"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13829"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000509923"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18161"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16255"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13392"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143597"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0016-8"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13989","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T21:09:25Z","timestamp":1703970565000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/ejh.13989"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13989","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"type":"print","value":"0902-4441"},{"type":"electronic","value":"1600-0609"}],"subject":[],"published":{"date-parts":[[2023,5,10]]},"assertion":[{"value":"2023-01-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}